Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple socks and gloves may shield cancer patients from Chemo's nerve pain

NCT ID NCT07464769

Prevention Sponsor: Region Jönköping County Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether wearing tight compression garments on hands and feet during chemotherapy can prevent nerve damage (peripheral neuropathy) caused by taxane or oxaliplatin drugs. About 358 breast and colorectal cancer patients will be randomly assigned to wear compression garments or not. Researchers will track nerve symptoms during treatment and for up to 5 years after.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
compression garments (class 2)
What this could lead to
If it works, this could offer a simple, drug-free way to prevent painful nerve damage from chemotherapy, helping cancer patients maintain quality of life.
What could go wrong
This is an early-stage study with no blinding, so results may be influenced by patient expectations. The effect may be small or not last long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 358 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Apr 2026

An estimate. Start dates often move.

Expected to finish

Dec 2033

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: o Scheduled neurotoxic treatment in any of the following settings: Taxane cohort * Breast cancer patients planned for either neoadjuvant or adjuvant taxane treatment Oxaliplatin cohort * Rectal cancer patients planned for total neoadjuvant treatment including oxaliplatin * Colorectal cancer patients planned for adjuvant chemotherapy including oxaliplatin, without prior neoadjuvant oxaliplatin treatment * Understand written and oral Swedish. Exclusion Criteria: * Previous neurotoxic chemotherapy\* treatment * Distant metastases * Any psychiatric disorder or health disorder that causes an inability to make an informed consent to participate. * Any manifest clinically significant peripheral neuropathy according to treating physician. * Current lymphoedema in limbs requiring compression therapy. * Ongoing pregnancy. * Planned taxane or oxaliplatin treatment shorter than 8 weeks or longer than 26 weeks * Planned compression or cryotherapy of hands and/or feet during taxane or oxaliplatin * Taxanes (docetaxel, paclitaxel, nabpaclitaxel), platinum components (carboplatin, oxaplatin, cisplatin), vinca-alkaloids (vincristine, vinblastine, vinorelbine, eribulin), bortezomid, thalidomide, antibody drug conjugate including vedotin or emtansine.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colorectal cancer colorectal neoplasm rectal cancer chemotherapy-induced neuropathy prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Peripheral neuropathy due to chemotherapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Linköping University

    Jönköping, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.